| 血清CEA水平与EGFR-TKI治疗晚期非小细胞肺癌疗效及预后分析 |
| |
| 引用本文： | 刘杰,成媛,贾永旭,张中冕,周云,马智勇,申淑景,李醒亚.血清CEA水平与EGFR-TKI治疗晚期非小细胞肺癌疗效及预后分析[J].第三军医大学学报,2011,33(7):728-731. |
| |
| 作者姓名： | 刘杰 成媛 贾永旭 张中冕 周云 马智勇 申淑景 李醒亚 |
| |
| 作者单位： | 刘杰,成媛,贾永旭,李醒亚,Liu Jie,Cheng Yuan,Jia Yongxu,Li Xingya(郑州大学,第一附属医院肿瘤科,郑州,450052);张中冕,Zhang Zhongmian(郑州大学,第二附属医院肿瘤科,郑州,450052);周云,Zhou Yun(郑州大学,第一附属医院放疗科,郑州,450052);马智勇,Ma Zhiyong(河南省人民医院肿瘤科,郑州,450003);申淑景,Shen Shujing(河南省肿瘤医院内科,郑州,450008) |
| |
| 摘 要： | 目的探讨非小细胞肺癌患者血清癌胚抗原(carcinoembryonic antigen,CEA)水平与EGFR-TKI治疗疗效及预后之间的关系。方法收集88例(腺癌69例,非腺癌19例)经吉非替尼或厄罗替尼治疗、疗效可评价的晚期非小细胞肺癌患者,有完整的血清CEA检测结果,分析CEA水平与EGFR-TKI药物治疗反应及预后之间的关系。结果血清CEA<5 ng/ml者的有效率(CR+PR)为18.2%(6/33),稳定率(SD)为18.2%(6/33),进展率为63.6%(21/33);CEA≥5 ng/ml者的有效率为30.9%(17/55),稳定率为43.6%(24/55),进展率为25.5%(14/55)。2组EGFR-TKI治疗的疗效差异有统计学意义(P=0.003)。血清CEA水平高的患者,服用TKI药物后疗效更好,而较低CEA值的患者效果较差。生存分析结果表明,血清CEA≥5 ng/ml组患者经EGFR-TKI治疗后有更长的无疾病进展时间及生存优势,差异有统计学意义(P=0.020,P=0.019)。结论血清CEA水平可作为预测晚期非小细胞肺癌患者服用EGFR-TKI药物疗效及预后指标。
|
| 关 键 词： | 癌胚抗原 EGFR酪氨酸激酶抑制剂 非小细胞肺癌 预后 |
Serum CEA level is associated with efficacy and prognosis of EGFR-TKI treatment in non-small cell lung cancer:report of 88 cases |
| |
| Liu Jie,Cheng Yuan,Jia Yongxu,Zhang Zhongmian,Zhou Yun,Ma Zhiyong,Shen Shujing,Li Xingya.Serum CEA level is associated with efficacy and prognosis of EGFR-TKI treatment in non-small cell lung cancer:report of 88 cases[J].Acta Academiae Medicinae Militaris Tertiae,2011,33(7):728-731. |
| |
| Authors: | Liu Jie Cheng Yuan Jia Yongxu Zhang Zhongmian Zhou Yun Ma Zhiyong Shen Shujing Li Xingya |
| |
| Institution: | Liu Jie1,Cheng Yuan1,Jia Yongxu1,Zhang Zhongmian2,Zhou Yun3,Ma Zhiyong4,Shen Shujing5,Li Xingya1(1Department of Oncology,5Department of Radiotherapy,First Affiliated Hospital,2Department of Oncology,Second Affiliated Hospital,Zhengzhou University,Zhengzhou,Henan Province,450052,3Department of Oncology,People's Hospital of Henan Province,450003,4Department of Internal Medicine,Tumor Hospital of Henan Province,450008,China) |
| |
| Abstract: | Objective To identify the correlation of the serum carcinoembryonic antigen(CEA) level and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) as a gene targeted drug in advanced non-small cell lung cancer(NSCLC).Methods We retrospectively reviewed 88 NSCLC patients,including 69 adenocarcinoma and 19 non-adenocarcinoma who admitted in our hospitals from July 2007 to November 2010.After at least 1 cycle of chemotherapy,they begun to take Gefitinib or Erlotinib.Their... |
| |
| Keywords: | carcinoembryonic antigen epidermal growth factor receptor tyrosine kinase inhibitor non-small cell lung cancer prognosis |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
